Eli Lilly and Company (LLY) DCF Valuation

Eli Lilly and Company (LLY) DCF Valoración

US | Healthcare | Drug Manufacturers - General | NYSE
Eli Lilly and Company (LLY) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Eli Lilly and Company (LLY) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Obtenga dominio sobre su análisis de valoración de Eli Lilly and Company (LLY) con nuestra sofisticada calculadora DCF! Precedido con datos reales (lly), esta plantilla de Excel le permite ajustar los pronósticos y los supuestos, lo que le permite calcular el valor intrínseco de Eli Lilly con precisión.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 22,319.5 24,539.8 28,318.4 28,541.4 34,124.1 38,022.2 42,365.6 47,205.1 52,597.5 58,605.8
Revenue Growth, % 0 9.95 15.4 0.78747 19.56 11.42 11.42 11.42 11.42 11.42
EBITDA 6,899.1 8,913.4 8,042.9 8,660.5 8,567.8 11,489.2 12,801.7 14,264.1 15,893.5 17,709.0
EBITDA, % 30.91 36.32 28.4 30.34 25.11 30.22 30.22 30.22 30.22 30.22
Depreciation 1,232.6 1,323.9 1,547.6 1,522.5 1,527.3 1,991.8 2,219.3 2,472.8 2,755.3 3,070.1
Depreciation, % 5.52 5.39 5.46 5.33 4.48 5.24 5.24 5.24 5.24 5.24
EBIT 5,666.5 7,589.5 6,495.3 7,138.0 7,040.5 9,497.4 10,582.4 11,791.2 13,138.2 14,639.0
EBIT, % 25.39 30.93 22.94 25.01 20.63 24.98 24.98 24.98 24.98 24.98
Total Cash 2,438.5 3,681.3 3,908.6 2,211.8 2,927.7 4,262.9 4,749.9 5,292.5 5,897.0 6,570.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 5,541.5 6,929.0 8,127.2 8,558.9 11,336.2
Account Receivables, % 24.83 28.24 28.7 29.99 33.22
Inventories 3,190.7 3,980.3 3,886.0 4,309.7 5,772.8 5,798.7 6,461.2 7,199.2 8,021.6 8,938.0
Inventories, % 14.3 16.22 13.72 15.1 16.92 15.25 15.25 15.25 15.25 15.25
Accounts Payable 1,405.3 1,606.7 1,670.6 1,930.6 2,598.8 2,518.8 2,806.5 3,127.1 3,484.4 3,882.4
Accounts Payable, % 6.3 6.55 5.9 6.76 7.62 6.62 6.62 6.62 6.62 6.62
Capital Expenditure -1,353.5 -2,029.1 -1,873.2 -2,484.0 -7,392.1 -3,902.1 -4,347.8 -4,844.5 -5,397.9 -6,014.5
Capital Expenditure, % -6.06 -8.27 -6.61 -8.7 -21.66 -10.26 -10.26 -10.26 -10.26 -10.26
Tax Rate, % 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05
EBITAT 4,990.7 6,501.8 5,889.8 6,549.0 5,628.9 8,284.0 9,230.3 10,284.8 11,459.6 12,768.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -2,457.1 3,820.9 4,524.2 4,992.1 -3,808.1 6,579.8 5,467.8 6,092.4 6,788.4 7,563.9
WACC, % 6.39 6.39 6.4 6.4 6.38 6.39 6.39 6.39 6.39 6.39
PV UFCF
SUM PV UFCF 26,922.4
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 7,866
Terminal Value 329,119
Present Terminal Value 241,460
Enterprise Value 268,382
Net Debt 22,407
Equity Value 245,976
Diluted Shares Outstanding, MM 903
Equity Value Per Share 272.31

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Eli Lilly and Company’s (LLY) financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for testing forecasts, validating strategies, and conserving time.

Key Features

  • Pre-Loaded Data: Eli Lilly’s historical financial statements and pre-filled forecasts.
  • Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
  • Instant Results: View Eli Lilly’s intrinsic value recalculated in real time.
  • Clear Visual Outputs: Dashboard charts illustrate valuation results and key metrics.
  • Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Eli Lilly data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Eli Lilly’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Eli Lilly and Company (LLY)?

  • Accuracy: Utilizes verified Eli Lilly financial data for precise calculations.
  • Flexibility: Allows users to experiment and adjust inputs as needed.
  • Time-Saving: Eliminate the complexity of constructing a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and detail expected by financial professionals.
  • User-Friendly: Intuitive interface suitable for users of all financial backgrounds.

Who Should Use This Product?

  • Investors: Accurately assess Eli Lilly’s fair value before making investment choices.
  • CFOs: Utilize a high-quality DCF model for financial reporting and analysis.
  • Consultants: Easily modify the template for valuation reports tailored to clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by Fortune 500 firms.
  • Educators: Implement it as a teaching resource to illustrate valuation techniques.

What the Template Contains

  • Pre-Filled Data: Includes Eli Lilly's historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Eli Lilly's profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.